Research Development Foundation
Records under this name other than the patents Research Development Foundation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 73 patents it holds.
Back to Research Development Foundation
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,017,754 | Attenuated virus strains and uses thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,175,058 | Soluble immune response suppressor polypeptides and treatment of multiple sclerosis and other autoimmune diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,081,795 | Flavivirus host range mutations and uses thereof Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,853,168 | Compositions for the reversible thioesterification of signaling proteins and methods of using same Formerly held Lapsed on the fee record Ended Oct 7, 2026 · High confidence | Lapsed on the fee record | Ended Oct 7, 2026 | High confidence |
| US 8,815,592 | Methods and Compositions Related to Dopaminergic Neuronal Cells Lapsed on the fee record Ended Aug 26, 2026 · High confidence | Lapsed on the fee record | Ended Aug 26, 2026 | High confidence |
| US 9,140,702 | Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis Term ended Term ended Jun 15, 2026 · From the USPTO record | Term ended | Term ended Jun 15, 2026 | From the USPTO record |
| US 9,645,148 | Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis Term ended Ended no later than Jun 15, 2026 · From the USPTO record | Term ended | Ended no later than Jun 15, 2026 | From the USPTO record |
| US 11,459,379 | Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis Term ended Term ended Jun 15, 2026 · From the USPTO record | Term ended | Term ended Jun 15, 2026 | From the USPTO record |
| US 7,575,924 | Methods and compositions relating to improved lentiviral vectors and their applications Term ended Term ended May 31, 2026 · From the USPTO record | Term ended | Term ended May 31, 2026 | From the USPTO record |
| US 8,663,637 | Methods and compositions for modulation of Olfml3 mediated angiogenesis Lapsed on the fee record Ended Mar 4, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 4, 2026 | From the USPTO record |